Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4–5

References

• Kuro O. Phosphate and klotho. Kidney Int Suppl 2011;79:S20–S23.
   Google Scholar
• Wesseling-Perry K, Wolf M. FGF23 in renal failure. In: Olgaard K, Salusky IB, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease, 2nd edn. Oxford: Oxford University Press; 2010. pp. 405–15.
   Google Scholar
• Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012;92: 131–55.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the ‘trade-off’ hypothesis. Clin J Am Soc Nephrol 2010;5: 1710–6.
   PubMed Web of Science ®Google Scholar
• Hofman-Bang J, Martuseviciene G, Santini MA, Olgaard K, Lewin E. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010;78:1119–27.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359: 584–92.
   PubMed Web of Science ®Google Scholar
• Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600–8.
   PubMed Web of Science ®Google Scholar
• Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432–9.
   PubMed Web of Science ®Google Scholar
• Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640–8.
   PubMed Web of Science ®Google Scholar
• Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John SM, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro O, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393–408.
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–201.
   Web of Science ®Google Scholar
• Slominski AT, Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, Yue J, Li W, Chen J, Nguyen MN, Tang EK, Miller D, Chen TC, Holick M. 20-hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol 2011;300:C526–C541.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911–30.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Lavie CJ, Holick MF. Vitamin D supplementation for cardiovascular disease prevention. JAMA 2011; 306:1546–7.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1529–39.
   PubMed Web of Science ®Google Scholar
• von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010;11:344–9.
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266–81.
   PubMed Web of Science ®Google Scholar
• Moe SM. Definition and classification of renal osteodystrophy and chronic kidney disease-mineral bone disorder (CKD-MBD). In: Olgaard K, Salusky IB, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease. 2nd edn. Oxford: Oxford University Press; 2010. pp. 1–14.
   Google Scholar
• Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82:737–47.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Isakova T, Smith K, Epstein M, Patel N, Wolf M. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant 2010;25:3970–7.
   PubMed Web of Science ®Google Scholar
• Cunningham J, Lewin E, Silver J. Medical therapy in chronic kidney disease. In: Olgaard K, Salusky IB, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease. 2nd edn. Oxford: Oxford University Press; 2010. pp. 463–83.
   Google Scholar
• Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8–28.
   PubMed Web of Science ®Google Scholar
• Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6:50–62.
   PubMed Web of Science ®Google Scholar
• Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Juppner H, Salusky IB. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011;79:112–9.
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA, Jurutka PW. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 2012;13:57–69.
   PubMed Web of Science ®Google Scholar
• Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008;18:375–82.
   PubMed Web of Science ®Google Scholar
• Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009;24:3799–805.
   PubMed Web of Science ®Google Scholar
• Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007;105:c132–c138.
   PubMed Web of Science ®Google Scholar
• Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008;23:4016–20.
   PubMed Web of Science ®Google Scholar
• Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007;27:36–43.
   Google Scholar
• Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956–66.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397–403.
   PubMedGoogle Scholar
• Negri AL. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. Nephrol Dial Transplant 2009;24:341–4.
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA. Vitamin D supplementation in CKD. Clin Nephrol 2011;75:286–93.
   PubMed Web of Science ®Google Scholar
• Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011;58:374–82.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ, Jr., Simon JF, Srinivas TR, Nally JV, Jr.Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011;58:536–43.
   Google Scholar
• Michos ED, Reis JP, Post WS, Lutsey PL, Gottesman RF, Mosley TH, Sharrett AR, Melamed ML. 25-Hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files. Nutrition 2012;28:367–71.
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115–25.
   PubMed Web of Science ®Google Scholar
• DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton ) 2006; 11:555–9.
   PubMed Web of Science ®Google Scholar
• Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney disease patients. Ren Fail 2008;30:407–10.
   PubMed Web of Science ®Google Scholar
• Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008;14:10–7.
   PubMedGoogle Scholar
• Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010;299:F882–9.
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008;3: 1144–51.
   PubMed Web of Science ®Google Scholar
• Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96: 53–8.
   PubMed Web of Science ®Google Scholar
• Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, Boehm BO, Grammer TB, Marz W. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011;26:3603–9.
   PubMed Web of Science ®Google Scholar
• Gotsman I, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, Admon D. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 2012;14: 357–66.
   PubMed Web of Science ®Google Scholar
• Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-OH Vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther 2011.Epub.
   Google Scholar
• Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26–34.
   PubMed Web of Science ®Google Scholar
• Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Jr., Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008;19:1379–88.
   PubMed Web of Science ®Google Scholar
• Inaguma D, Nagaya H, Hara K, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Kurata K. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 2008;12:126–31.
   PubMed Web of Science ®Google Scholar
• Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1128–35.
   PubMed Web of Science ®Google Scholar
• Pilz S, Dobnig H, Tomaschitz A, Kienreich K, Meinitzer A, Friedl C, Wagner D, Piswanger-Solkner C, Marz W, Fahrleitner-Pammer A. Low 25-hydroxyvitamin D is associated with increased mortality in female nursing home residents. J Clin Endocrinol Metab 2012;97:E653–57.
   PubMed Web of Science ®Google Scholar
• Schottker B, Ball D, Gellert C, Brenner H. Serum 25- hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2012.Epub.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674–84.
   PubMed Web of Science ®Google Scholar
• Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 2012;7:624–32.
   PubMed Web of Science ®Google Scholar
• Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol 2010;163:825–31.
   PubMed Web of Science ®Google Scholar
• Lewin E, Olgaard K. Vitamin D in CKD: a continuous challenge. NephSAP 2010;9:273–7.
   Google Scholar